The GPD2 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human SK-HEP-1 hepatoma line, engineered to disrupt the GPD2 gene. This loss-of-function model enables investigation of glycerol-3-phosphate dehydrogenase 2 (GPD2) in a relevant cancer cell background without introducing clonal bias. The polyclonal knockout format preserves cellular heterogeneity, making it suitable for population-level studies of metabolic adaptation and gene function.
SK-HEP-1 is a mesenchymal-like liver cancer cell line originally isolated from the ascites of a patient with liver adenocarcinoma. It displays both epithelial and endothelial characteristics and is widely employed as a model for tumor metastasis and metabolic reprogramming. The line??s unique dual phenotype provides a platform to examine how metabolic pathway alterations influence cancer cell behavior, particularly in the context of hepatocellular carcinoma.
GPD2 is a mitochondrial enzyme that catalyzes the oxidation of glycerol-3-phosphate (G3P) to dihydroxyacetone phosphate (DHAP) on the outer face of the inner mitochondrial membrane, using FAD as a cofactor. This reaction is the mitochondrial arm of the glycerol phosphate shuttle, which couples cytosolic glycolysis to oxidative phosphorylation. Electrons from FADH2 are transferred directly to the ubiquinone pool, bypassing complex I, and subsequently flow through complex III and complex IV. The activity of GPD2 is regulated by PPAR??, PGC-1??, thyroid hormone, and insulin, and it functions with cytosolic GPD1 to maintain redox balance. Downstream, GPD2 modulates the NAD+/NADH ratio, mitochondrial membrane potential, and ROS generation, thus influencing cellular energetics.
In SK-HEP-1 cells, GPD2 knockout allows dissection of the glycerol phosphate shuttle’s role in cancer metabolism. These cells exhibit metabolic plasticity; disrupting GPD2 can reveal how complex I bypass affects mitochondrial respiration and the Warburg effect. Comparing the polyclonal knockout population with parental controls enables evaluation of changes in substrate utilization, ATP production, and the glycolysis?Coxidative phosphorylation balance, offering insights into liver cancer metabolic adaptations.
This knockout model supports applications in cancer metabolism, Warburg effect investigation, mitochondrial dysfunction modeling, and metabolic inhibitor screening. Assays such as Seahorse respirometry, glycerol-3-phosphate dehydrogenase activity assays, NAD+/NADH ratio measurements, ROS detection (DCFDA, MitoSOX), and metabolomics profiling are particularly relevant. Cell viability under glucose deprivation can further probe metabolic dependencies. For additional information, please contact Ascent Research.
